ACR Convergence 2022 conference coverage | Skip to main content

ACR Convergence 2022

ACR Convergence 2022 top stories

Debate (concept)

18-11-2022 | ACR 2022 | Conference coverage | News

A Great Debate: To treat or not to treat in pre-RA?

In one of two Great Debate sessions at ACR Convergence 2022 in Philadelphia, Pennsylvania, USA, two experts teamed up to provide opposing stands on whether now is the right time to be treating people at risk for rheumatoid arthritis in the preclinical stages of the condition in order to prevent disease onset.

3D illustration of Lungs

15-11-2022 | ACR 2022 | Conference coverage | News

RECITAL: Rituximab represents alternative to cyclophosphamide for CTD-ILD

Rituximab and cyclophosphamide have similar overall efficacy in patients with connective tissue disease-associated interstitial lung disease, but rituximab may be associated with fewer adverse events, suggest findings from a phase 2b trial.

Close up of medical disposable syringe and vial

14-11-2022 | ACR 2022 | Conference coverage | News

Phase 3 trial supports add-on telitacicept for SLE

Addition of the recombinant fusion protein telitacicept to standard care may reduce disease activity and is well tolerated in people with systemic lupus erythematosus, research suggests.

Expert video interviews

Xenofon Baraliakos

23-11-2022 | ACR 2022 | Conference coverage | Video

SURPASS: Secukinumab vs adalimumab biosimilar in axSpA

Xenofon Baraliakos takes us through SURPASS, a phase 3b head-to-head trial that demonstrated equivalence of secukinumab versus adalimumab biosimilar in patients with radiographic axial spondyloarthritis.

Stay informed with Medicine Matters

Get the latest developments in rheumatology delivered straight to your inbox

News from ACR Convergence 2022

23-11-2022 | ACR 2022 | Conference coverage | News

LOUiSSe study shows remibrutinib efficacy in Sjögren’s syndrome

Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, has shown potential for the treatment of Sjögren's syndrome in a phase 2 study.

21-11-2022 | ACR 2022 | Conference coverage | News

Abortion restrictions impede methotrexate access for some rheumatology patients

Patients with rheumatic diseases have reported issues with access to methotrexate following changes to abortion laws, show findings from a questionnaire study conducted in the USA.

17-11-2022 | ACR 2022 | Conference coverage | News

Secukinumab comparable to adalimumab biosimilar in axSpA

Researchers have found that secukinumab performs equally well to adalimumab biosimilar for the treatment of radiographic axial spondyloarthritis in a head-to-head trial.

17-11-2022 | ACR 2022 | Conference coverage | News

New score could predict ILD development in people with SSc

Researchers have developed the ILD-RISC score, which has the potential to predict the development of interstitial lung disease in patients with systemic sclerosis.

16-11-2022 | ACR 2022 | Conference coverage | News

JUVE-BASIS: Support for baricitinib in juvenile arthritis

The Janus kinase inhibitor baricitinib has the potential to be “an important part of the treatment landscape” for juvenile arthritis, research suggests.

16-11-2022 | ACR 2022 | Conference coverage | News

PD-1 receptor agonist may represent a novel treatment for patients with RA

Peresolimab, a PD-1 receptor agonist, may represent a promising approach to treating rheumatoid arthritis, with an “encouraging” safety profile, suggests research reported at the ACR Convergence 2022 in Philadelphia, Pennsylvania, USA.

15-11-2022 | ACR 2022 | Conference coverage | News

Community-based diet, exercise program could benefit people with knee osteoarthritis

A diet and exercise program delivered in community settings may improve some clinical outcomes for people with knee osteoarthritis and overweight or obesity, suggest findings from the WE-CAN pragmatic randomized controlled trial.

15-11-2022 | ACR 2022 | Conference coverage | News

COVID-19 vaccination advocated for pregnant women with RMDs

COVID-19 vaccination should be actively promoted for women with rheumatic and musculoskeletal diseases who are pregnant or planning a pregnancy, say researchers.

14-11-2022 | ACR 2022 | Conference coverage | News

Longer duration of mycophenolate pause may improve COVID-19 vaccine response

Discontinuation of mycophenolate mofetil for at least 10 days is associated with an improved antibody response to COVID-19 vaccination among people with rheumatic diseases, research suggests.

14-11-2022 | ACR 2022 | Conference coverage | News

Genicular nerve block may provide short-term pain relief for knee osteoarthritis

Early trial results suggest that ultrasound-guided genicular nerve block may represent a promising short-term treatment option for pain associated with knee osteoarthritis.

This information is brought to you by Medicine Matters in partnership with medwireNews and is not sponsored by, nor a part of, the  American College of Rheumatology.